Multiplex Assay Kit for Synuclein Alpha (SNCa) ,etc. by CBA (Cytometric Bead Array)

SNC-A; aSYN; PD1; PARK1; PARK4; NACP; Non-A Beta Component Of Alzheimer's Disease Amyloid Precursor Protein; Non-A4 component of amyloid precursor

Specificity

This assay has high sensitivity and excellent specificity for detection of Synuclein Alpha (SNCa) ,etc. by CBA (Cytometric Bead Array).
No significant cross-reactivity or interference between Synuclein Alpha (SNCa) ,etc. by CBA (Cytometric Bead Array) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Synuclein Alpha (SNCa) ,etc. by CBA (Cytometric Bead Array) and the recovery rates were calculated by comparing the measured value to the expected amount of Synuclein Alpha (SNCa) ,etc. by CBA (Cytometric Bead Array) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 85-93 88
EDTA plasma(n=5) 86-93 89
heparin plasma(n=5) 81-103 99

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Synuclein Alpha (SNCa) ,etc. by CBA (Cytometric Bead Array) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Synuclein Alpha (SNCa) ,etc. by CBA (Cytometric Bead Array) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Synuclein Alpha (SNCa) ,etc. by CBA (Cytometric Bead Array) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 78-93% 88-95% 90-99% 78-96%
EDTA plasma(n=5) 96-104% 87-99% 89-97% 96-104%
heparin plasma(n=5) 97-104% 91-99% 80-90% 89-103%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity

Assay procedure summary

1. Add 200μL analysis buffer solution to each well of the plate for pre-wetting;
2. Preparation of standards, reagents and samples before the experiment;
3. Add 100μL standard or sample to each well, add 10μL magnetic beads, and incubate 120 minutes protect from light at 25°C on shaker;
4. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60 minutes protect from light at 25°C on shaker;
5. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent B, and incubate 30 minutes protect from light at 25°C on shaker;
6. Wash plate once on magnetic frame;
7. Add 100μL sheath fluid, swirl for 10 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
The Journal of Clinical Investigation Cerebrospinal fluid–based kinetic biomarkers of axonal transport in monitoring neurodegeneration PubMed: PMC3428100
Neurobiology of Disease Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission PubMed: PMC3107939
Nature Communications Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus PubMed: PMC3265381
Provisional chapter Mutations of PARK Genes and Alpha-Synuclein and Parkin Concentrations in Parkinson’s Disease Intechopen:Source
Nerodegeneration Apolipoprotein Eε4: A Biomarker for Executive Dysfunction among Parkinson's Disease Patients with Mild Cognitive Impairment pubmed:29326545
Experimental gerontology The anti-aging protein klotho alleviates injury of nigrostriatal dopaminergic pathway in 6-hydroxydopamine rat model of Parkinson's disease: Involvement of PKA/CaMKII/CREB signaling. pubmed:29107062
Neurobiology of Disease Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity Pubmed: 30521842
molecular and cellular biochemistry Potential therapeutic effects of antagonizing adenosine A2A receptor, curcumin and niacin in rotenone-induced Parkinson's disease mice model Pubmed: 31820278
International Journal of Pharmacology Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's disease Pubmed: 32084576
EBioMedicine Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys Pubmed: 32810825
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPB222Hu01 Recombinant Synuclein Alpha (SNCa) Positive Control; Immunogen; SDS-PAGE; WB.
PAB222Hu01 Polyclonal Antibody to Synuclein Alpha (SNCa) WB,IHC
LAB222Hu71 Biotin-Linked Polyclonal Antibody to Synuclein Alpha (SNCa) WB; IHC; ICC.
MAB222Hu22 Monoclonal Antibody to Synuclein Alpha (SNCa) WB; IHC; ICC; IP.
SEB222Hu ELISA Kit for Synuclein Alpha (SNCa) Enzyme-linked immunosorbent assay for Antigen Detection.
AEB222Hu ELISA Kit for Anti-Synuclein Alpha Antibody (Anti-SNCa) Enzyme-linked immunosorbent assay for Antibody Detection.
CMB222Hu Multiplex Assay Kit for Synuclein Alpha (SNCa) ,etc. by CBA (Cytometric Bead Array) FLIA Kit for Antigen Detection.
LMB222Hu Multiplex Assay Kit for Synuclein Alpha (SNCa) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.